111 Inc - ADR

111, Inc. engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies. The B2B segment includes the sale of pharmaceutical products to pharmacy customers through 1 Drug Mall. The company was founded by Gang Yu and Jun Ling Liu in May 2013 and is headquartered in Shanghai, China.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

111 Inc achieves operational profitability in Q1 2024 earnings call

111 Inc's Q1 2024 performance reflects a shift towards profitability, driven by operational efficiency and strategic initiatives. While facing challenges in expense optimization, the company is well-positioned to capitalize on market opportunities through listing options and expansion plans.

111 Inc reports operational profitability and strategic growth initiatives in Q2 2024

111 Inc's Q2 2024 earnings call showcased operational profitability, cost reductions, and strategic advancements in digital transformation and supply chain management. The company's focus on growth in the health care industry, expansion of patents, and plans for further logistics network development position it for continued success amidst challenges and evolving market trends.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

111, Inc. kept growing despite strong headwinds from pandemic lockdowns, which will continue to plague Q2 but not enough to lower FY22 outlook. 111, Inc. has plenty of growth avenues, particularly in high-margin services, which are growing at 70% from a very small base.

111, Inc.'s Inexorable Drive Towards Profitability

111, Inc. (NASDAQ:YI ) Q1 2022 Earnings Conference Call June 16, 2022 7:30 AM ET Company Participants Monica Mu - Investor Relations Director Junling Liu - Co-Founder, Chairman and Chief Executive Officer Luke Chen - Chief Financial Officer, Major Subsidiary Harvey Wangg - Chief Operating Officer Conference Call Participants Xipeng Feng - CICC Jessie Lu - HSBC Zoe Bian - Citi Operator Good day and thank you for standing by. Welcome to the First Quarter 2022 Earnings Conference Call.

111, Inc.'s (YI) CEO Junling Liu on Q1 2022 Results - Earnings Call Transcript

SHANGHAI , June 16, 2022 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced its unaudited financial results for the first quarter ended March 31, 2022. First Quarter 2022 Highlights Net revenues were RMB2.98 billion (US$470.5 million), representing an increase of 14.9% year-over-year.

111, Inc. Announces First Quarter 2022 Unaudited Financial Results

SHANGHAI, May 26, 2022 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2022, before the U.S. market opens on Thursday, June 16, 2022. 111's management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on Thursday, June 16, 2022 (7:30 PM Beijing Time on the same day).

111 to Announce First Quarter 2022 Unaudited Financial Results on June 16, 2022 - Conference Call to Follow

SHANGHAI , May 5, 2022 /PRNewswire/ -- 111 Inc. ( "111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company in China, today announced that on May 4th, 2022, the Securities and Exchange Commission (the "SEC") provisionally listed the Company as a "Commission-Identified Issuer" under the Holding Foreign Companies Accountable Act of the United States (the "HFCAA"). This identification was expected by the Company as a routine application procedure following the Company's filing of its annual report on Form 20-F for the fiscal year ended December 31, 2021 on April 29th, 2022.

111, Inc. Provides Updates on its Status Under the Holding Foreign Companies Accountable Act

SHANGHAI , April 13, 2022 /PRNewswire/ -- On April, 2022, 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company in China,  has set up an "Anti-Epidemic Command" at the first opportunity to coordinate its relevant departments and manpower to fully participate in the fight against the pandemic in Shanghai. As a provider of anti-epidemic items and drugs in Shanghai, 111 has so far opened various supporting services, including antigen test product supplies, an exclusive speedy procurement channel, chronic disease medication registration, free online consultation, and prescription renewal for chronic diseases.

111, Inc. Provides Urgently-needed Items and Online Services to Support Shanghai's Fight Against Covid-19 Pandemic

111, Inc. (YI) CEO Junling Liu on Q4 2021 Results - Earnings Call Transcript

SHANGHAI, March 17, 2022 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2021. Fourth Quarter 2021 Highlights Net revenues were RMB3.46 billion (US$543.1 million), representing an increase of 30.9% year-over-year.

111, Inc. Announces Fourth Quarter and Fiscal Year 2021 Financial Results

SHANGHAI, March 14, 2022 /PRNewswire/ -- On March 14, 2022, 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company signed a strategic cooperation agreement with Shenzhen BGI Co., Ltd. (SZ: 300676) under which BGI will supply its SARS-CoV-2 Virus Antigen Detection Kits (Immunofluorescence Chromatography) across China via 111's online pharmacy, 1 Pharmacy, in an effort to boost epidemic prevention and control nationwide.

111, Inc. Becomes First Online Retail Platform for BGI's SARS-CoV-2 Virus Antigen Detection Kits

SHANGHAI, March 4, 2022 /PRNewswire/ -- On February 23, 2022, 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company in China, signed a strategic cooperation agreement on direct supply with Xi'an Beilin Pharmaceutical Co., Ltd. ("Beilin Pharmaceutical").

111, Inc. Reaches Strategic Partnership on Direct Supply with Beilin Pharmaceutical to Blaze New Trails in Digital Development of Chinese Patent Medicine

SHANGHAI, Feb. 22, 2022 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced that it will report its unaudited financial results for the fourth quarter and fiscal year 2021 ended December 31, 2021, before the U.S. market opens on Thursday, March 17, 2022. 111's management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on Thursday, March 17, 2022 (7:30 PM Beijing Time on the same day).

111 to Announce Fourth Quarter and Fiscal Year 2021 Unaudited Financial Results on March 17, 2022 - Conference Call to Follow

111, Inc. (YI) CEO Junling Liu on Q3 2021 Results - Earnings Call Transcript

SHANGHAI, Nov. 19, 2021 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced its unaudited financial results for the third quarter ended September 30, 2021. Third Quarter 2021 Highlights Net revenues were RMB3.35 billion (US$519.3 million), representing an increase of 41.6% year-over-year.

111, Inc. Announces Third Quarter 2021 Unaudited Financial Results

SHANGHAI, Oct. 28, 2021 /PRNewswire/ – 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2021, before the U.S. market opens on Friday, November 19, 2021. 111's management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on Friday, November 19, 2021 (7:30 PM Beijing Time on the same day).

111 to Announce Third Quarter 2021 Unaudited Financial Results on November 19, 2021 - Conference Call to Follow

SHANGHAI, Oct. 25, 2021 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced a strategic cooperation agreement with Chugai Pharma China Co., Ltd. ("Chugai Pharma China").

111, Inc. Announces Strategic Partnership with Chugai Pharma China Co., Ltd. to Accelerate Innovations in Chronic Disease Management

Key takeaways: 111's revenue grew 87% in second quarter, generally outpacing its peers, as it aims to more than double its fulfillment capacity this year

Solid Earnings, Modest Buyback Fail to Boost Drug Seller 111 Inc.

SHANGHAI, Sept. 17, 2021 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced that Senior Vice President, Investor Relations and Business Development, Tiffany ZhuGe, will present an update on the Company's business and host one-on-one meetings with investors at the Cantor Global Healthcare Conference, which is being held virtually on September 27-30, 2021.

111, Inc. Announces Participation in the Cantor Virtual Global Healthcare Conference

SHANGHAI, Sept. 7, 2021 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced that its board of directors (the "Board") has authorized a share repurchase program under which the Company may repurchase up to $10 million of its Class A ordinary shares in the form of American depositary shares ("ADSs") in the next twelve months (collectively, the "Share Repurchase Program").

111, Inc. Announces $10 Million Share Repurchase Program

111, Inc. (YI) CEO Junling Liu on Q2 2021 Results - Earnings Call Transcript

SHANGHAI, Aug. 27, 2021 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced its unaudited financial results for the second quarter ended June 30, 2021. Second Quarter 2021 Highlights Net revenues were RMB3.0 billion (US$468.4 million), representing an increase of 86.5% year-over-year.

111, Inc. Announces Second Quarter 2021 Unaudited Financial Results

A diamond in the rough is a pretty rare find, especially among Chinese stocks.

This Is the Only Chinese Stock I Would Buy Right Now

SHANGHAI, Aug. 16, 2021 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced the expansion of its existing partnership with Bayer Healthcare Co. Ltd. ("Bayer").

111, Inc. Deepens Partnership with Bayer Healthcare

SHANGHAI, Aug. 9, 2021 /PRNewswire/ – 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced that it will report its unaudited financial results for the second quarter ended June 30, 2021, before the U.S. market opens on Friday, August 27, 2021. 111's management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on Friday, August 27, 2021 (7:30 PM Beijing Time on the same day).

111 to Announce Second Quarter 2021 Unaudited Financial Results on August 27, 2021 -Conference Call to Follow

SHANGHAI, Aug. 3, 2021 /PRNewswire/ – 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced a strategic cooperation agreement with Suzhou Zelgen Biopharmaceuticals Co., Ltd. ("Zelgen") (688266.SH), an innovative drug R&D and production company.

111, Inc. Enters into Strategic Cooperation Agreement with Zelgen to Develop a New Management Platform for Liver Cancer Patients in China

JD.com

Yirendai Ltd. Sponsored

Looking to invest in America's top rival? Here are your best bets.

News for 111 Inc - ADR Stock (YI)